Protalix stock plunges after negative CHMP opinion on dosing regimen
NegativeFinancial Markets

Protalix's stock has taken a significant hit following a negative opinion from the CHMP regarding its dosing regimen. This development is crucial as it raises concerns about the company's future prospects and could impact investor confidence. The CHMP's feedback is a critical step in the regulatory process, and such setbacks can lead to decreased market value and potential delays in product availability.
— Curated by the World Pulse Now AI Editorial System